These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 7842822)

  • 1. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
    J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K; Inoue E; Mitsuhashi S
    Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of piperacillin, ceftazidime, cefepime and cefpirome against Pseudomonas aeruginosa strains with intrinsic ticarcillin resistance.
    Bert F; Setbon PG; Lambert-Zechovsky N; Branger C
    Chemotherapy; 1996; 42(6):426-31. PubMed ID: 8957576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa.
    Valdes JM; Baltch AL; Smith RP; Hammer MC; Ritz WJ
    J Antimicrob Chemother; 1990 Apr; 25(4):575-84. PubMed ID: 2112539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin.
    Fu KP; Foleno BD; Lafredo SC; LoCoco JM; Isaacson DM
    Antimicrob Agents Chemother; 1993 Feb; 37(2):301-7. PubMed ID: 8452361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Wakai Y; Kamimura T; Tawara S; Matsumoto S; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1993 Jan; 46(1):88-98. PubMed ID: 8436563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa.
    Neu HC; Chin NX; Novelli A
    Antimicrob Agents Chemother; 1988 Nov; 32(11):1666-75. PubMed ID: 3150915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
    Giamarellos-Bourboulis EJ; Grecka P; Tsitsika A; Tympanidou C; Giamarellou H
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.
    Fung-Tomc J; Huczko E; Kolek B; Thater C; Kessler RE
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2652-4. PubMed ID: 1810203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
    Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
    J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.
    Gradelski E; Fung-Tomc J; Huczko E; Kessler RE
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():75-80. PubMed ID: 8150769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of cefpirome compared with that of other agents.
    Raizes EG; Cantey JR
    J Antimicrob Chemother; 1988 Feb; 21(2):177-81. PubMed ID: 3129388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.